Article Sidebar
Published:
Jun 26, 2026DOI:
10.4314/ahs.v26i2.5Keywords:
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
Enterococcus faecium multicenter antimicrobial resistance surveillance in Tunisia (2010-2022): high vancomycin resistance rates and linezolid resistance emergence
Abstract
Background: Vancomycin-resistant Enterococcus faecium is classified among World Health Organization priority pathogens for Research and development of new antibiotics. This study presents the results of 13-year surveillance of antibiotic resistance in E. faecium, with a specific focus on vancomycin and linezolid resistance in thirteen university hospitals across various regions of Tunisia.
Methods: All participating laboratories followed a standardized methodology for clinical sample culture, bacterial identification, antibiotic susceptibility testing according to CA-SFM guidelines, result interpretation, epidemiological data collection. Additionally, they implemented quality controls.
Findings: During the surveillance period, 2,931 E. faecium isolates were collected, predominantly from urine (49.1%) and blood cultures (24%), with high prevalence in Surgery Departments (30.3%) and Intensive Care Units (23.6%). Resistance rates were high for ampicillin (87.1%), erythromycin (93.6%), gentamicin (62.8%) and vancomycin (26%). Since 2019, six linezolid-resistant isolates have been isolated and only one isolate resistant to tigecycline was identified in 2021. Vancomycin resistance had significant upward trend since 2012, peaking at 38.1% in 2017. It was significantly associated to gentamicin (84.9% vs. 53.8%) (p<0.0001) and erythromycin95.8% vs. 89.6%) (p=0.0001) in a five year period (2018 - 2022).
Conclusion: This worrying situation requires deeper investigations to develop adapted strategies with targeted measures in high-risk departments.
Keywords: Enterococcus faecium; vancomycin resistance; linezolid resistance.
